HER2 Signaling Workgroup.
Important papers, files, and meeting updates can be found in the Box folder. Link:
The current members are:
Joe Gray (firstname.lastname@example.org)
Jim Korkola (email@example.com)
Spencer Watson (firstname.lastname@example.org)
Bill Muller (email@example.com)
Xiaolin Nan (firstname.lastname@example.org)
Koie Chin (chinkoei(ohsu.edu)
Summer Gibs (email@example.com)
Kimberly Beatty (firstname.lastname@example.org)
Sunjong Kwon (email@example.com)
Joe Garay (firstname.lastname@example.org)
Heidi Feiler (email@example.com)
The purpose of this group is to determine aspects of HER2 signaling in HER2 amplified cancer cells that can serve as the basis for near-term publications. New data demonstrates how the tumor microenvironment has subtype-specific effects on cancer cells that have the capacity to rewire internal signaling, and cause anti-HER2 therapeutics to become growth stimulants. This potentially involves: novel heterodimers, RTK feedback loops, overexpression of exogenous growth factors, intercellular trafficking, and morphological changes.
The preliminary figure below illustrates some proposed mechanisms in luminal HER2+ cell lines for how lapatinib treatment can result in enhanced growth when there are high levels of exogenous NRG1.